Sexual Desire Disorder (Hypoactive Sexual Desire Disorder)

Sexual desire disorders include hypoactive sexual desire disorder (HSDD, in men) and female sexual interest/arousal disorder (FSIAD, in women per DSM-5), characterized by persistent or recurrent deficient or absent sexual fantasies, thoughts, urges, or desire for sexual activity causing clinically significant distress or interpersonal difficulty for at least 6 months. Distinction from normal variation in desire (mismatched desire in couples, age-related changes, situational reduction) is important — pathological diagnosis requires personal distress. Subtypes: lifelong (since beginning of sexual activity) vs acquired (after period of normal function), generalized (with all partners and situations) vs situational (only specific contexts/partners), partner-specific factors, relationship factors, individual vulnerability factors, cultural/religious factors, medical factors. Prevalence: 5-15% of women, higher in postmenopausal (low estrogen, vaginal dryness, dyspareunia, mood changes); 2-5% of men, increasing with age (testosterone decline). FSIAD reflects updated understanding that female desire often follows arousal (responsive desire), unlike traditional spontaneous desire model.

Etiology is multifactorial requiring biopsychosocial assessment. Biological factors: hormonal (low testosterone in men with hypogonadism, low estrogen in postmenopausal women, hyperprolactinemia, thyroid dysfunction, hyperandrogenism in women), medical conditions (depression, anxiety, chronic illness, cardiovascular disease, diabetes, neurological disorders, malignancy), medications (SSRIs and SNRIs antidepressants — sexual side effects in 30-70%, antipsychotics, beta-blockers, oral contraceptives, anti-androgens, opioids, alcohol), pelvic conditions (dyspareunia, vaginismus, endometriosis, vulvodynia in women; erectile dysfunction in men), pregnancy and postpartum period, lactation, perimenopause and menopause. Psychological factors: depression (50-90% of depressed patients have sexual dysfunction), anxiety disorders, body image distress, history of sexual abuse or trauma, relationship problems, communication issues, performance anxiety, religious or cultural inhibitions, stress and fatigue, low self-esteem.

Diagnostic evaluation includes detailed sexual history (lifelong vs acquired, generalized vs situational, partner factors, distress level, functional impact), medical history and physical examination, mental health screening for depression and anxiety, relationship assessment, hormonal evaluation if indicated (testosterone in men, prolactin, thyroid, FSH/LH, estradiol), validated questionnaires (Female Sexual Function Index, International Index of Erectile Function, Sexual Desire Inventory). Treatment is biopsychosocial: address underlying medical conditions and medications (medication adjustment when possible), treat co-occurring mental health conditions, sex therapy and couples therapy (cognitive-behavioral, communication training, sensate focus exercises, mindfulness-based interventions), education about normal sexual response and desire variability, lifestyle modifications (stress management, exercise, sleep, alcohol moderation), partner involvement in treatment. Pharmacological options for FSIAD in premenopausal women: flibanserin (Addyi) — oral 5-HT1A agonist/5-HT2A antagonist, modest efficacy, sedation and hypotension side effects, no alcohol; bremelanotide (Vyleesi) — subcutaneous melanocortin receptor agonist on-demand, modest efficacy, nausea and flushing common. Hormonal: estrogen replacement for postmenopausal women, vaginal estrogen for genitourinary syndrome, testosterone in men with hypogonadism, off-label transdermal testosterone for select women (controversial, monitor side effects), DHEA. PDE-5 inhibitors for men with concomitant erectile dysfunction. For SSRI-induced sexual dysfunction: drug holiday, switch to bupropion or vortioxetine, add bupropion or buspirone augmentation. Long-term outcomes vary; complete resolution uncommon but improvement in 30-60% with comprehensive treatment.